212 related articles for article (PubMed ID: 30299427)
1. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
[TBL] [Abstract][Full Text] [Related]
2. Amikacin population pharmacokinetics among paediatric burn patients.
Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
[TBL] [Abstract][Full Text] [Related]
3. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
[TBL] [Abstract][Full Text] [Related]
7. Estimation of once-daily amikacin dose in critically ill adults.
Šíma M; Hartinger J; Cikánková T; Slanař O
J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.
Caceres Guido P; Perez M; Halac A; Ferrari M; Ibarra M; Licciardone N; Castaños C; Gravina LP; Jimenez C; Garcia Bournissen F; Schaiquevich P
Pediatr Pulmonol; 2019 Nov; 54(11):1801-1810. PubMed ID: 31402602
[TBL] [Abstract][Full Text] [Related]
9. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
[TBL] [Abstract][Full Text] [Related]
11. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
Illamola SM; Colom H; van Hasselt JG
Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of gentamicin in patients with cancer.
Rosario MC; Thomson AH; Jodrell DI; Sharp CA; Elliott HL
Br J Clin Pharmacol; 1998 Sep; 46(3):229-36. PubMed ID: 9764963
[TBL] [Abstract][Full Text] [Related]
14. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Lugo G; Castañeda-Hernández G
Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of amikacin in a Korean clinical population.
Jang SB; Lee YJ; Park MS; Song YG; Kim JH; Kim HK; Ahn BS; Park K
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):371-81. PubMed ID: 21612744
[TBL] [Abstract][Full Text] [Related]
19. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
[TBL] [Abstract][Full Text] [Related]
20. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.
Akers KS; Cota JM; Frei CR; Chung KK; Mende K; Murray CK
Antimicrob Agents Chemother; 2011 Oct; 55(10):4639-42. PubMed ID: 21825289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
